Chapter 9 Neural Injury at the Molecular Level
The histopathologic appearance of chronic cervical spondylotic myelopathy has been well described and includes the characteristic features of regional demyelination extending axially from the site of compression, preferential lateral column axonal loss, and anterior horn neuron dropout.1–5 Ongoing research projects are creating a better understanding of myelopathy on a molecular level, and recent studies indicate that a significant portion of cell loss appears to be caused by the process of programmed cell death, also known as apoptosis. Although the molecular pathways regulating apoptosis are extremely complex, programmed cell death affects restricted populations of spinal cord cells—including oligodendrocytes and some neuronal and astrocytic subpopulations—suggesting the possibility that targeted antiapoptotic therapy may be a reasonable goal for the treatment or prevention of myelopathy.
Microbiology of the Oligodendrocyte
The oligodendrocyte has been shown to play a pivotal role in several complex biologic processes, including development, injury repair, disease process modulation, and the formation and maintenance of myelin.6,7 During the early stages of human development, a large oligodendroglial population is generated, and an estimated 50% of these cells eventually disappear by the process of apoptosis.8 As the central nervous system matures, the oligodendroglia become responsible for the creation and maintenance of myelin sheaths. These sheaths, although formed directly from oligodendroglial cell membrane, demonstrate key biochemical differences from the parent cell membrane in terms of both chemical and protein composition.9 The biochemical and physiologic characteristics of the relatively small protein constituent are especially important, and absence or alteration of the major protein components (i.e., proteolipid protein or myelin basic protein) can lead to the advent of severe demyelinating disease.10 Another unique feature of the oligodendrocyte is the high concentration of microtubules, which contribute to formation of an elaborate cytoskeletal framework, allowing myelin sheath formation at remote distances from the cell karyon.6
Considerable progress has been made in understanding the response of oligodendroglial cells to injury, and a more complete understanding of this complex process may lead to a greater appreciation of the mechanism of injury in such processes as cervical spondylotic myelopathy. Studies suggest that the oligodendrocyte is particularly sensitive to a wide range of oxidative, chemical, radiation-induced, and mechanical injuries. High iron content and relatively inefficient antioxidant defense mechanisms appear to render the oligodendrocyte vulnerable to oxidative stress.11–14 Injury-related release of intracellular iron may contribute to the generation of damaging hydroxyl radicals through the Fenton reaction.15 In addition, in vitro exposure of mature oligodendrocytes to hydrogen peroxide has been shown to induce apoptotic cell death, but preincubation of these cells with an iron chelator, such as deferoxamine, appears to confer some protection from oxidative cytotoxicity and apoptosis.16,17
Toxins that impair mitochondrial respiration, such as cuprizone and ethidium bromide, have also been shown to trigger apoptosis in oligodendroglial cells. Subsequently, these chemicals have been used to develop experimental models of demyelinating disease and injury. It has been established that radiation exposure directly damages DNA and has been shown to lead to apoptotic cell death in many cell types. However, several studies of delayed neurologic injury after radiation therapy have revealed that oligodendrocytes are the most radiation-sensitive cell population in spinal cord tissue.18,19
In addition to the previously mentioned sources of oligodendrocyte injury, mechanical stress has been repeatedly shown to trigger oligodendrocyte apoptosis. Mechanical injury appears capable of triggering a specific immune response with formation of antibodies and subsequent cytotoxicity directed against oligodendrocyte antigens.20 This immune-mediated injury may be caused by macrophage activity and appears to involve several different cytokines, such as tumor necrosis factor, lymphotoxin, and gamma-interferon.21–24 These activated macrophages also generate free radicals and nitric oxide, which have been shown to lead to apoptosis.25,26 Formation of the membrane attack complex through activation of the complement cascade is another consequence of macrophage activation and has been implicated in oligodendrocyte injury.
In addition to the macrophage, at least two specific subpopulations of T cells may also be involved in oligodendroglial apoptosis. CD4+ T cells adhere to target cells through the Fas receptor identified on oligodendrocyte cells, thereby triggering apoptosis. Gamma-delta T cells have been found to co-localize with oligodendrocytes (expressing heat-shock protein 65), and may trigger cell death through production of gamma-interferon.27
Apoptosis
Apoptosis, also known as “programmed cell death,” may be the primary cellular process underlying the disappearance of oligodendrocytes in the earliest histologic stages of traumatic spinal cord injury (SCI) and other processes such as cervical spondylotic myelopathy. The process of apoptosis is distinct from necrosis and involves a sequence of intracellular events that includes chromatin aggregation and internucleosomal DNA fragmentation, nuclear pyknosis, and subsequent cell shrinkage.28,29 Apoptosis ultimately results in phagocytic engulfment of cells without extracellular discharge of cytosolic contents, and without generation of a local inflammatory response.30
In contrast to necrotic cell death, apoptosis is a much more abbreviated process that has made its study relatively difficult. Apoptotic cells initially shrink and lose contact with adjacent cells, forming membrane blebs and expressing prophagocytic cell surface signals. The cell chromatin then condenses and fragments, and the process ends in compartmentalization of the entire cell into small, membrane-bound vesicles that are quickly phagocytized. By comparison, cell necrosis is a relatively prolonged affair that is characterized by cell membrane disruption, mitochondrial swelling, random DNA cleavage, and the generation of a local inflammatory reaction.31
Several molecular biology assays have been developed for identification of apoptosis in various settings. A marker of DNA cleavage, such as the terminal deoxynucleotidyltransferase (TdT)-mediated nick-end labeling (TUNEL) technique, is a popular assay. Interpretation of studies relying solely on TUNEL staining has been criticized as possibly being limited by the observation that this method has been found to label cells undergoing necrosis as well and may not be as specific for apoptosis as once thought.31 Internucleosomal DNA cleavage, a hallmark of apoptosis, is demonstrated by a characteristic “laddering” pattern on gel electrophoresis, and this finding can reinforce the results of TUNEL staining. The most specific method for identifying apoptotic cells, however, remains direct histologic examination and the identification of chromatin condensation along the nuclear periphery, condensation of the cytoplasm with intact organelles, and membrane blebbing.32 A newly developed commercial assay is also available that uses monoclonal antibody to single-stranded DNA (Apostain; eBioscience, San Diego, CA). This method is purported to detect the earliest stages of apoptosis occurring before DNA fragmentation and supposedly has no cross-reactivity for necrotic cells.33
Molecular Mechanisms of Apoptosis
The molecular pathways involved in apoptosis have been extensively examined, but were initially studied in the roundworm, Caenorhabditis elegans. These studies led to the discovery of one of the first genes associated with apoptosis, which was appropriately named CED 3 in honor of this worm.34 Subsequently, a homologous family of apoptosis-related protein products has been identified in mammals and termed the CED 3/ICE (interleukin-1β-converting enzyme) family.35–37 These proteins, also known as caspases, serve as functional cysteine proteases.38 At least 10 distinct members of this gene family have been identified thus far, and at least 2 of these proteins, caspase-3 and caspase-9, have been strongly associated with apoptosis in human cells.39,40 The intracellular cascade involving caspase-3 ends in activation of specific endonucleases that cleave DNA strands into the characteristic internucleosomal fragments.41 Production of these 185 base-pair fragments results in the DNA laddering that is one of the histologic hallmarks of apoptosis. Activation of caspase-9 appears specifically to induce mitochondrial release of cytochrome c, which is one of the earliest intracellular events in apoptosis.42 Targeted inhibition of caspase-1 (ICE) and caspase-3 (CPP-32) in oligodendrocytes has been shown to prevent apoptotic death of these cells.40
As previously described, numerous chemical and biologic triggers for apoptosis have been identified. Mature oligodendrocytes are particularly sensitive to oxidative stress.11 Experimental exposure of oligodendroglial cells to hydrogen peroxide leads to increased expression and nuclear translocation of transcription factors nuclear factor-κB (NF-κB) and activator protein-1 (AP-1), both implicated as critical elements in the apoptotic pathway.17
One of the most important biologic triggers of oligodendrocyte apoptosis in SCI may be tumor necrosis factor-α (TNF-α). TNF-α has been shown to induce apoptosis in oligodendrocytes, both in vitro and in vivo.43–45 Designated death domains located on the intracellular side of the type I receptor for TNF-α (TNFR1) and related receptors have been associated with activation of caspase-3 and caspase-8, which subsequently leads to apoptosis.40 Gamma-interferon may further enhance susceptibility of oligodendrocytes to TNF-α-triggered apoptosis through up-regulation of the so-called death receptor, Fas.46 It has also been reported that the p38 and Jun N-terminal kinase (JNK) pathways play a role in the transmission of apoptosis signals following SCI. Further findings indicate that activation of JNK by TNF-α promotes expression of apoptosis signal-regulating kinase 1 (ASK1).47
The oligodendrocyte apoptotic signal transduction pathway appears to begin with ligand binding to either Fas (CD95 or Apo1) or p75 (low-affinity neurotrophin receptors) cell surface receptors. These proteins are members of the TNFR family and have been shown to co-localize with cells undergoing apoptosis in a rat model of cervical SCI.32 Binding of Fas ligand (FasL) to the extracellular cysteine-rich domain of Fas results in formation of oligomers, which allows interaction of the intracellular death domain with Fas-associated death domain protein (FADD).48 Once the association is made, the death domain of FADD then interacts with procaspases 8 and 10 and triggers a caspase activation cascade that ultimately ends in activation of at least three different effector enzymes, caspases 3, 6, and 7.32 These effector molecules presumably interact with additional downstream targets, ultimately leading to cell apoptosis.49 FLICE (FADD-like interleukin-1β-converting enzyme) proteins are proteins demonstrating sequence homology with the caspases, but acting as inhibitors of the apoptosis-triggering pathway.50
Another important apoptosis pathway involves the p53 tumor suppressor protein, as well as the proteins p21, Bcl-2, and Bax.51 In a rat model of SCI, p53 protein appeared within 30 minutes of injury, co-localizing with apoptotic glial cells and spreading in distribution over the course of 2 days.51 Cellular studies have further demonstrated that exposure of oligodendroglial cells to hydrogen peroxide leads to rapid translocation of p53 from the cytosol to the nucleus and cell death by apoptosis.52
Apoptosis in Traumatic Spinal Cord Injury
It has been well established that cell loss in traumatic SCI occurs both at the time of injury and secondarily over a period of days to weeks after the event. At the epicenter of injury, the majority of cell death occurs through necrosis, with macrophages and microglia becoming actively engaged in phagocytosis of necrotic cell debris.53 However, cell loss in spinal cord white matter continues throughout a much more extensive axial section of the cord for up to several weeks in a process referred to as secondary injury. Although it has become apparent that this continued cell loss significantly worsens neurologic outcome in SCI, the underlying biologic mechanisms remain poorly understood. Several studies have suggested, however, that the primary process involves oligodendrocyte apoptosis.54–59
Initial evidence that apoptosis contributes to ongoing cell death after acute SCI came from animal studies involving the rat.60 It was demonstrated that acute compressive cord injury leads to preferential apoptosis of oligodendrocytes along degenerating longitudinal white matter tracts.55 These initial findings were subsequently supported by similar results in other animal models, including primates.56 In most of these animal studies, visible signs of oligodendrocyte apoptosis appear within 24 hours and continue for at least 3 weeks after injury.54–57,60–63
A histopathologic study of human SCI indicates that oligodendrocyte cell death by apoptosis can continue from 3 hours to at least 8 weeks after injury.64 In this study, oligodendrocyte apoptosis appeared to correlate with specific patterns of wallerian degeneration and was associated with intracellular activation of caspase-3. Apoptosis was more pronounced in ascending white matter tracts, and the authors speculated that this finding may reflect the histopathologic observation that wallerian degeneration affects ascending tracts before descending ones.65 The extent of oligodendrocyte apoptosis was shown to correlate with the severity of neurologic injury, being significantly less extensive in patients with incomplete neurologic deficits. This correlation of apoptosis and neurologic impairment is in agreement with previous findings from animal studies.57 Of note, neuronal apoptosis was not seen, suggesting that neuronal loss occurs through the process of necrosis.
The biochemical trigger for oligodendrocyte apoptosis related to traumatic SCI is currently unknown but is likely to be multifactorial. It has been observed that SCI is characterized by significant intracellular Ca2+ shifts, and several apoptotic processes are Ca2+ dependent, including DNA fragmentation and proteolysis.66,67 Similarly, acute SCI has been associated with hypoxia and free radical formation, which are also established triggers of apoptosis.68,69 Glutamate excitotoxicity has also been implicated in secondary SCI and appears to lead to apoptotic cell death.70
Animal models have provided most of the information regarding biochemical responses to SCI. A rat model of SCI has demonstrated increased local TNF-α expression within 1 hour of injury, followed by increased nitric oxide levels at 4 hours.71 This model used a neutralizing antibody against TNF-α, and significantly reduced nitric oxide levels as well as the extent of apoptosis. Similarly, addition of a nitric oxide synthase inhibitor, N-monomethyl-l-arginine acetate (L-NMMA) also reduced the number of apoptotic cells. These findings suggest that TNF-α signaling triggers apoptotic cell death after SCI, and that this effect is at least partly mediated by nitric oxide. Of note, the amount of decrease in apoptosis after administration of L-NMMA (42%) was less than half that observed after TNF-α antibody administration (89%), implying the existence of multiple parallel apoptotic pathways. A recent study by Genovese et al. demonstrated the neuroprotective effects of selective adenosine A2A receptor agonists, which act by decreasing the overall expression of myeloperoxidase, NF-κB, and inducible nitric oxide synthase (iNOS), and decreasing the activation of JNK mitogen-activated protein kinase (MAPK) in oligodendrocytes.72 In addition, another recent study found that mice with SCI, when treated with ethyl pyruvate, showed no increase of TNF-α expression and a decrease in oligodendrocyte apoptosis.73
Several studies of development suggest that specific trophic factors are produced by axons and that absence of these factors results in oligodendrocyte apoptosis.74–76 Members of the neuregulin ligand family, in particular the glial growth factor (GGF), bind to the HER4 receptor on the surface of oligodendrocytes and appear to play an important role in cell differentiation and survival.77 Alternatively, the traumatic event may result in direct release of proapoptotic factors into spinal cord tissue. It is well established that activated microglia release several factors that may cause apoptosis, including TNF-α, reactive oxygen intermediates, and nitric oxide.78,79 Administration of exogenous thyroid hormone (triiodothyronine [T3]) during the early period after acute SCI has also been found to increase the population of apoptotic cells.80
Apoptosis in Chronic Spinal Cord Compression
Several studies have suggested an important role for ischemic tissue injury in the pathogenesis of myelopathy in the setting of cervical spondylosis. On the cellular level, the sensitivity of oligodendrocytes to hypoxic injury is well established and appears to support the possibility of an ischemic cause.81 However, neurons are relatively more vulnerable to ischemic injury, and their sparing in early myelopathy makes a purely ischemic cause for cervical spondylotic myelopathy somewhat unlikely.
Although necrosis and apoptosis often occur simultaneously, distinguishing the two processes provides important information regarding the causes of specific disease processes. Although ischemia has been associated with apoptotic cell death, severe ischemia is characteristically thought to result in cell necrosis. Because oligodendrocyte disappearance in both trauma and chronic spondylotic myelopathy is apoptotic in nature, it is thought that mechanisms other than pure ischemia are involved.55
Animal models strongly support a role for apoptotic cell death in the tissue degeneration seen in chronic, compression-related cervical myelopathy. The tiptoe-walking Yoshimura (twy) mouse is a specific strain of inbred mouse that has been useful as a model for chronic spinal cord compression.82 Twy mice become quadriparetic 4 to 8 months after birth because of the development of local hyperostosis along the dorsolateral margins of the C1 and C2 vertebrae, which results in severe cord compression at this level.83 Histologic examination of spinal cord tissue from these mice has revealed a characteristic pattern of descending degeneration affecting the anterior and lateral columns and ascending degeneration along the posterior columns. These findings are in addition to severe tissue damage at the level of compression.84 Cavity formation and myelin ovoids (myelin debris) were observed extending from the zone of compression into adjacent levels without gross deformation of the spinal cord. Detection of apoptotic cells using the TUNEL assay revealed a distribution of glial apoptosis that appeared to mirror the pattern of degeneration, whereas cell-specific staining confirmed that apoptotic cells were oligodendrocytes. The investigators included an autopsy study of a human patient dying with cervical myelopathy resulting from ossification of the posterior longitudinal ligament, in which a pattern of neuronal loss, demyelination, and apoptosis was observed that was similar to the findings in the twy mouse. Further studies of the twy mouse showed increased expression of TNFR1 and TNFR2 in chronically compressed spinal cord tissue, which further elucidates the effect of chronic compression on apoptosis and demyelination.85
Oligodendrocyte survival depends on the presence of specific so-called survival factors produced by neighboring axons, leading to the possibility that oligodendroglial cell loss merely reflects prior neuronal injury. However, oligodendrocyte apoptosis likely precedes axonal degeneration in chronic myelopathy, as evidenced by both human and animal studies of spinal cord compression demonstrating apoptotic oligodendrocytes in the setting of intact demyelinated axons.65,86,87
Prevention of Apoptosis
Oxidative stress has been shown to be a potent trigger for apoptotic death of oligodendrocytes.16 Conversely, antioxidant therapy with pyrrolidine dithiocarbamate (PDTC) and vitamin E appears to moderate this effect considerably.17 The asymmetric distribution of phospholipid polar-head groups across the plasma membrane bilayer may play a role in determining vulnerability to oxidative stress.88 Normally, there is an over-representation of choline phosphoglyceride and sphingomyelin in the outer leaflet, whereas the aminophospholipids, ethanolamine phosphoglyceride (EPG) and serine phosphoglyceride (SPG), are over-represented in the inner leaflet. Apoptosis has been associated with redistribution of SPG and EPG and loss of aminophospholipid asymmetry.89 The large, polyunsaturated, fatty acid content of both SPG and EPG makes them targets for propagating free radical reactions, leading to generation of lipid peroxides and apoptosis.15,90 It therefore makes sense that increasing polyunsaturated fatty acid content through addition of docosahexaenoic acid enhances the sensitivity of oligodendrocytes to oxidative stress and thereby results in increased rates of apoptosis.88 Conversely, reducing EPG synthesis using N-monomethylethanolamine and N,N-dimethylethanolamine (DMEA) supplements appears to rescue cells from apoptotic death.
Methylprednisolone treatment has been shown to protect the spinal cord from injury and has become a standard component of SCI protocols. The protective effect of steroid therapy may be mediated in part by an inhibitory effect on oligodendrocyte apoptosis. Intraperitoneal injection of rats with dexamethasone after SCI significantly decreases the extent of apoptosis in both neurons and glial cells.91 At least part of this effect may be mediated through inhibition of TNF-α and NF-κB.92 A more recent study has also shown some additional benefit to the intraperitoneal administration of pregabalin in a post-SCI rat model.93 Treatment with pregabalin showed a significant decrease in expression of caspase-3, Bcl-2, and p38 MAPK compared with control and methylprednisolone treatment groups. All three of these factors have been shown to be key components of the inflammatory and apoptotic cascades.94–97
The role of TNF-α in oligodendrocyte apoptosis appears complex and at times contradictory. Most studies have demonstrated primarily toxic effects, leading to apoptosis in several different models. This form of TNF-α-induced oligodendrocyte apoptosis can be inhibited in vitro by insulin-like growth factor 1 (IGF-1).45 However, a few studies have suggested that TNF-α may, in certain instances, protect oligodendrocytes from apoptosis.43,98,99
The effects of TNF-α can be better understood through a description of its molecular mechanisms. TNF-α exerts its biologic effects through binding of two different cell surface receptors, the type 1 receptor (TNFR1) and the type 2 receptor (TNFR2).100 TNFR binding has been shown to prevent neuronal apoptosis in several studies.101–103 TNFR binding leads to increased NF-κB expression, and this TNFR-NF-κB signal transduction pathway has been identified as possibly a key endogenous, antiapoptotic cellular mechanism.104–107 NF-κB is a transcription factor that increases expression of several genes, resulting in increased production of cellular inhibitor of apoptosis protein 2 (c-IAP2).108,109 c-IAP2, in turn, inhibits apoptosis through binding TNFR-associated factor 2.
Protein inhibitors of apoptosis have been studied in baculovirus, and homologues to these proteins, referred to as inhibitors of apoptosis proteins (IAPs), have been identified in mammalian cells. IAPs appear to exert antiapoptotic effects through inhibition of the caspase cascade.110–113
Recent evidence suggests that activation of the TNFR-NF-κB pathway is important in protecting spinal cord cells from apoptosis after SCI. In an animal model of SCI, rats lacking TNFR1 demonstrated decreased spinal cord tissue levels of NF-κB activity, lower levels of c-IAP2, and increased caspase-3 activity. Apoptosis was significantly increased, the overall lesion size was larger with more extensive demyelination and axonal disruption, and functional recovery was significantly worsened.114
These studies suggested that pharmacologic modulation of TNF-α levels may yield benefits in patients with myelopathy or SCI. For example, interleukin-10 reduces TNF-α levels in the spinal cord and has been shown to improve functional recovery from SCI in rats.115
Although inflammatory demyelinating disease represents a pathologic process distinct from traumatic injury, the generation of high levels of TNF-α leading to oligodendrocyte apoptosis in both demyelinating disease and SCI implies potentially useful biochemical similarities.116,117 Bcl-2 is a protein with antiapoptotic properties that is produced by certain types of cells, including oligodendrocytes. The activity of Bcl-2 has been studied in a rat model of human T-lymphocyte virus type I (HTLV-I)-associated myeloneuropathy. In this model, rats develop chronic progressive hind-limb weakness because of apoptotic oligodendrocyte death in the spinal cord.118 A recent study using this rat model has associated oligodendrocyte apoptosis with enhanced sensitivity to exogenous TNF-α and an associated down-regulation of Bcl-2 in affected cells.119 It is therefore conceivable that endogenous production of antiapoptotic proteins such as Bcl-2 can be up-regulated therapeutically as a treatment strategy for SCI and cervical myelopathy.55–57,64,79,120–123
In the developing central nervous system, oligodendrocytes appear to be protected from apoptosis by molecular, and possibly electrical, signals provided through axonal contact.124–126 Several studies have demonstrated that exposure to specific cytokines protects oligodendrocytes from apoptosis. IGF-1 prevents TNF-α-triggered apoptosis in cell culture.45 A study of transgenic mice expressing high levels of IGF-1 demonstrated decreased oligodendrocyte death after exposure to the demyelinating toxin cuprizone.127 In addition, fibroblast growth factor triggers oligodendrocyte dedifferentiation and confers protection from apoptosis.128–130
Serum growth factor deprivation has also been shown to lead to apoptosis in cultured oligodendrocytes. This model of apoptosis has been used to study the role of the complement system in apoptosis. Although assembly of the membrane attack complex, C5b-9, on cell membranes typically leads to formation of transmembrane channels and resultant cell death, sublytic levels of C5b-9 complement components activate the cell cycle and enhance cell survival by preventing apoptosis.131,132 This antiapoptotic effect appears to involve down-regulation of the proapoptotic cytosolic protein Bcl-2 antagonist of cell death (BAD).133 Studies suggest that a delicate balance exists between the protective antiapoptotic effects of the membrane-bound Bcl-2 and Bcl-XL proteins and the proapoptotic cytosolic proteins Bcl-2-associated X protein (BAX) and BAD.134 This balance appears to determine functional mitochondrial integrity and, consequently, whether a cell will undergo apoptosis.
Glutamate excitotoxicity represents yet another potential trigger for oligodendrocyte apoptosis.135 Oligodendrocytes express α-amino-3-hydroxy-5-methyl-4-isoxazolpropionic acid (AMPA)/kainite-type glutamate receptors and have been shown to be exquisitely sensitive to glutamate toxicity.136 The specific receptor antagonist 2,3-dihydroxy-6-nitro-7-sulfamyl-benzo(f)quinoxaline (NBQX) has been shown to protect oligodendrocytes from glutamate both in vitro and in vivo.136,137
Finally, the process of apoptosis requires active protein synthesis. Inhibition of protein synthesis in animal models using the chemotherapeutic agent cycloheximide leads to a reduction in apoptotic cell death, less severe histopathologic changes, and improved clinical recovery.57
Biomechanical Deformation as an Epigenetic Factor in Neuronal and Oligodendrocytic Apoptosis
Although the environmental sensitivity of oligodendrocytes has been stressed, it should be remembered that specific stresses will trigger apoptosis in neurons. In particular, biomechanical factors have been shown to be an important epigenetic factor in driving neuronal apoptosis. Stretch-related myelopathy and brainstem injury are substantiated in the literature.138–147 Neuronal strain (stretch) acts on the Na+ channel mechanoreceptors to increase Na+ influx, reverse cation exchange pumps, and depolarize voltage-gated Ca2+ channels, resulting in pathologic calcium influx.148 Sublethally damaged neurons also undergo up-regulation of N-methyl-d-aspartate receptors, resulting in heightened vulnerability to subsequent challenges of reactive oxygen species and peroxynitrites, concomitant mitochondrial dysfunction, and DNA fragmentation.149 Stretching neurons induces early calpain activation and contributes to progressive intra-axonal structural damage and apoptosis of neurons and oligodendrocytes.57,149,150 Stretch injury has been shown to induce phosphorylation of p38 MAPK and apoptosis in vascular, heart, and lung cells.151 The molecular events in neurons and oligodendrocytes should therefore be viewed within the matrix of environmental biomechanical stresses to which the organism is exposed.
Discussion
Identification of apoptosis per se does not provide much insight into the potential causes of specific disorders, including cervical myelopathy. Many sources of injury can result in histologically identical apoptotic cell death, including both mechanical trauma and ischemia.55,152,153 Various studies have identified oligodendrocyte apoptosis in response to axonal injury and after exposure to specific cytokines, as well as due to apparent genetic susceptibility.75,98,154 Adding to the complexity, apoptotic pathways appear to interact with one another in reinforcing relationships. Products of lipid peroxidation-induced cell damage, such as 4-hydroxynonenal (4-HNE), have been shown to enhance extracellular concentrations of glutamate by reducing their uptake, and they also appear capable of inducing apoptosis.58,155
Moreover, devising specific treatment strategies based on an incomplete understanding of the complex molecular mechanisms underlying apoptosis can be potentially hazardous. As previously discussed, several studies have pointed out the opposing effects of TNF-α on oligodendrocyte apoptosis.156,157
Another example of a molecule with potentially activating and inhibiting effects on apoptosis is nitric oxide. The observation that nitric oxide exposure can trigger both apoptotic and necrotic cell death in oligodendrocytes has led to efforts to protect the spinal cord from secondary injury through modulation of nitric oxide levels.26,158,159 However, a neurotoxicant-induced model of demyelination in genetically engineered mice lacking inducible nitric oxide synthase (iNOS) revealed significantly more extensive oligodendrocyte apoptosis after cuprizone exposure, compared with control animals.160 This result suggests a potentially protective effect of nitric oxide in some cases of acute demyelination.
Apoptosis is an important determinant of morbidity in cervical spondylotic myelopathy, as well as secondary SCI. Understanding the apoptotic mechanisms involved in these conditions will help to provide insight into potential targets for therapeutic intervention. Recognition that apoptosis plays a principal role in this process has introduced the possibility that the rational design of protease inhibitors active against specific proteins, such as caspase-3, may favorably modulate the response of spinal cord tissue to multiple forms of injury. Nevertheless, the molecular pathways governing apoptosis are extensive and interdependent, and a thorough understanding is absolutely necessary if any attempt at improving myelopathic outcome through modulation of this process is to succeed.
Casha S., Yu W.R., Fehlings M.G. Oligodendroglial apoptosis occurs along degenerating axons and is associated with FAS and p75 expression following spinal cord injury in the rat. Neuroscience. 2001;103:203-218.
Emery E., Aldana P., Bunge M.B., et al. Apoptosis after traumatic human spinal cord injury. J Neurosurg. 1998;89:911-920.
Hisahara S., Shoji S., Okano H., et al. ICE/CED-3 family executes oligodendrocyte apoptosis by tumor necrosis factor. J Neurochem. 1997;69:10-20.
Inukai T., Uchida K., Nakajima H., et al. Tumor necrosis factor-alpha and its receptors contribute to apoptosis of oligodendrocytes in the spinal cord of spinal hyperostotic mouse (twyy/twy) sustaining chronic mechanical compression. Spine (Phila Pa 1976). 2009;34:2848-2857.
Lee Y.B., Yune T.Y., Baik S.Y., et al. Role of tumor necrosis factor-alpha in neuronal and glial apoptosis after spinal cord injury. Exp Neurol. 2000;166:190-195.
Rowland J.W., Hawryluk G.W., Kwon B., et al. Current status of acute spinal cord injury pathophysiology and emerging therapies: promise on the horizon. Neurosurg Focus. 2008;25:E2.
1. Kameyama T., Hashizume Y., Ando T., et al. Spinal cord morphology and pathology in ossification of the posterior longitudinal ligament. Brain. 1995;118:263-278.
2. Mair W.C.P., Druckman R. The pathology of spinal cord lesions and their relation to the clinical features in protrusion of cervical intervertebral discs. Brain. 1953;76:70-91.
3. Ono K., Ota H., Tada K., et al. Cervical myelopathy secondary to multiple spondylotic protrusions: a clinicopathologic study. Spine (Phila Pa 1976). 1977;2:109-125.
4. Bohlmann H.H., Emery S. The pathophysiology of cervical spondylosis and myelopathy. Spine (Phila Pa 1976). 1988;13:843-846.
5. Wilkinson M. The morbid anatomy of cervical spondylosis and myelopathy. Brain. 1960;83:589-617.
6. Pfeiffer S.E., Warrington A.E., Bansal R. The oligodendrocyte and its many cellular processes. Trends Cell Biol. 1994;3:191-197.
7. Ludwin S.K. The pathobiology of the oligodendrocyte. J Neuropathol Exp Neurol. 1997;56:111-124.
8. Barres B.A., Raff M.C. Control of oligodendrocyte number in the developing rat optic nerve. Neuron. 1994;12:935-942.
9. McLaurin J.A., Yong V.W. Oligodendrocytes and myelin. Neurol Clin. 1995;13:23-49.
10. Duncan I.D. Inherited disorders of demyelination of the central nervous system. In: Kettenmann H., Ransom B., editors. Neuroglia. New York: Oxford University Press; 1995:990-1009.
11. Smith K.J., Kapoor R., Felts P.A. Demyelination: the role of oxygen and nitrogen species. Brain Pathol. 1999;9:69-92.
12. Gelman B.B. Iron in CNS disease. J Neuropathol Exp Neurol. 1995;54:477-486.
13. Connor J.R., Menzies S.L. Relationship of iron to oligodendrocytes and myelination. Glia. 1996;17:83-93.
14. Thorburne S.K., Juurlink B.H.K. Low glutathione and high iron govern the susceptibility of oligodendroglial precursors to oxidative stress. J Neurochem. 1996;67:1014-1022.
15. Halliwell B. Reactive oxygen species and the central nervous system. J Neurochem. 1992;59:1609-1623.
16. Richter-Landsberg C., Vollgraf U. Mode of cell injury and death after hydrogen peroxide exposure in cultured oligodendroglia cells. Exp Cell Res. 1998;244:219-229.
17. Vollgraf U., Wegner M., Richter-Landsberg C. Activation of AP-1 and NF-κB transcription factors is involved in hydrogen peroxide-induced apoptotic cell death of oligodendrocytes. J Neurochem. 1999;73:2501-2509.
18. Li Y.Q., Wong C.S. Apoptosis and its relationship with cell proliferation in the irradiated rat spinal cord. Int J Radiat Biol. 1998;74:405-417.
19. Li Y.Q., Jay V., Wong C.S. Oligodendrocytes in the adult rat spinal cord undergo radiation-induced apoptosis. Cancer Res. 1996;56:5417-5422.
20. Brosnan C.F., Raine C.S. Mechanisms of immune injury in multiple sclerosis. Brain Pathol. 1996;6:243-257.
21. Hartung H.P., Jung S.F., Stoll G., et al. Inflammatory mediators in demyelinating disorders of the CNS and PNS. J Neuroimmunol. 1992;40:197-210.
22. Friede R.L., Brack W. Macrophage functional properties during myelin degradation. Adv Neurol. 1993;59:327-336.
23. Selmaj K., Raine C.S., Farooq M., et al. Cytokine cytotoxicity against oligodendrocytes: apoptosis induced by lymphotoxin. J Immunol. 1991;147:1522-1529.
24. McLaurin J.A., D’Souza S., Stewart J., et al. Effect of tumor necrosis factor α and β on human oligodendrocytes and neurons in culture. Int J Dev Neurosci. 1995;13:369-381.
25. Brett R., Rumsby M. Evidence of free radical damage in the central nervous system of guinea pigs at the prolonged acute and early relapse stages of chronic relapsing experimental allergic encephalomyelitis. Neurochem Int. 1993;23:35-44.
26. Merrill J.E., Ignarro L.J., Sherman M.P., et al. Microglial cell cytotoxicity of oligodendrocytes is mediated through nitric oxide. J Immunol. 1993;151:2132-2141.
27. Selmaj K., Brosnan C.F., Raine C.S. Colocalization of lymphocytes bearing gamma delta T cell receptor and heat shock protein hsp65 oligodendrocytes in multiple sclerosis. Proc Natl Acad Sci U S A. 1991;88:6452-6456.
28. Hockenberry D. Defining apoptosis. Am J Pathol. 1995;146:16-19.
29. Kane A.B. Redefining cell death. Am J Pathol. 1995;146:1-2.
30. Cohen J.J. Apoptosis. Immunol Today. 1993;14:126-130.
31. Majno G., Joris I. Apoptosis, oncosis, and necrosis: an overview of cell death. Am J Pathol. 1995;146:3-15.
32. Casha S., Yu W.R., Fehlings M.G. Oligodendroglial apoptosis occurs along degenerating axons and is associated with FAS and p75 expression following spinal cord injury in the rat. Neuroscience. 2001;103:203-218.
33. Frankfurt O.S., Robb J.A., Sugarbaker E.V., et al. Monoclonal antibody to single-stranded DNA is a specific and sensitive cellular marker of apoptosis. Exp Cell Res. 1996;226:387-397.
34. Horwitz H.R., Ellis H.M., Sternberg D.W. Programmed cell death in nematode development. Neurosci Comment. 1982;1:56-65.
35. Fraser A., Evan G. A license to kill. Cell. 1996;85:781-784.
36. Martin S.J., Green D.R. Protease activation during apoptosis: death by a thousand cuts? Cell. 1995;82:349-352.
37. Nagata S. Apoptosis by death factor. Cell. 1997;88:355-365.
38. Eldadah B.A., Faden A.I. Caspase pathways, neuronal apoptosis and CNS injury. J Neurotrauma. 2000;17:811-829.
39. Ellis R.E., Yvan J., Horvitz H.R. Sequential activation of ICE-like and CPP32-like proteases during Fas-mediated apoptosis. Nature. 1991;380:723-726.
40. Hisahara S., Shoji S., Okano H., et al. ICE/CED-3 family executes oligodendrocyte apoptosis by tumor necrosis factor. J Neurochem. 1997;69:10-20.
41. Janicke R.U., Sprengart M.L., Wati M.R., et al. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem. 1997;273:9357-9360.
42. Nicholson D.W., Thornberry N.A. Caspases: killer proteases. Trends Biochem Sci. 1997;22:299-306.
43. D’Souza S., Alinauskas K., McCrea E., et al. Differential susceptibility of human CNS-derived cell populations to TNF-dependent and independent immune-mediated injury. J Neurosci. 1994;15:7293-7300.
44. Sipe K.J., Srisawasdi D., Dantzer R., et al. An endogenous 55 kDa TNF receptor mediates cell death in a neural cell line. Mol Brain Res. 1996;38:222-232.
45. Ye P., D’Ercole J. Insulin-like growth factor I protects oligodendrocytes from tumor necrosis factor-alpha-induced injury. Endocrinology. 1999;140:3063-3072.
46. Pouly S., Becher B., Blain M., et al. Interferon-gamma modulates human oligodendrocyte susceptibility to Fas-mediated apoptosis. J Neuropathol Exp Neurol. 2000;59:280-286.
47. Takenouchi T., Setoguchi T., Yone K., et al. Expression of apoptosis signal-regulating kinase 1 in mouse spinal cord under chronic mechanical compression. Spine (Phila Pa 1976). 2008;33:1943-1950.
48. Ashkenazi A., Dixit V.D. Death receptors: signaling and modulation. Science. 1998;281:1305-1308.
49. Muzio M., Salvesen G.S., Dixit V.M. FLICE induced apoptosis in a cell-free system. J Biol Chem. 1997;272:2952-2956.
50. Tschopp J., Irmler M., Thome M. Inhibition of Fas death signals by FLIPs. Curr Opin Immunol. 1998;10:552-558.
51. Saito N., Yamamoto T., Watanabe T., et al. Implications of p53 protein expression in experimental spinal cord injury. J Neurotrauma. 2000;17:173-182.
52. Uberti D., Yavin E., Gil S., et al. Hydrogen peroxide induces nuclear translocation of p53 and apoptosis in cells of oligodendroglia origin. Brain Res Mol Brain Res. 1999;65:167-175.
53. Grossman S.D., Rosenberg L.J., Wrathall J.R. Temporal-spatial pattern of acute neuronal and glial loss after spinal cord contusion. Exp Neurol. 2001;168:273-282.
54. Katoh K., Ikata T., Katoh S., et al. Induction and its spread of apoptosis in rat spinal cord after mechanical trauma. Neurosci Lett. 1996;216:9-12.
55. Li G.L., Brodin G., Farooque M., et al. Apoptosis and expression of Bcl-2 after compression trauma to rat spinal cord. J Neuropathol Exp Neurol. 1996;55:280-289.
56. Crowe M.J., Bresnahan J.C., Shuman S.L., et al. Apoptosis and delayed degeneration after spinal cord injury in rats and monkeys. Nat Med. 1997;3:73-76.
57. Liu X.Z., Xu X.M., Hu R., et al. Neuronal and glial apoptosis after traumatic spinal cord injury. J Neurosci. 1997;17:5395-5406.
58. Springer J.E., Azbill R.D., Knapp P.E. Activation of the caspase-3 apoptotic cascade in traumatic spinal cord injury. Nat Med. 1999;5:943-946.
59. Barina M. Neuroscience’s meeting of the minds in Washington. Science. 1996;274:1466.
60. Crowe M.J., Shuman S.L., Masters J.N., et al. Morphological evidence suggesting apoptotic nuclei in spinal cord injury. Soc Neurosci Abstr. 1995;21:232.
61. Beattie M.S., Farooqui A.A., Bresnahan J.C. Review of current evidence for apoptosis after spinal cord injury. J Neurotrauma. 2000;17:915-925.
62. Nakahara S., Yone K., Sakou T., et al. Induction of apoptosis signal regulating kinase 1 (ASK1) after spinal cord injury in rats: possible involvement of ASK1-JNK and p38 pathways in neuronal apoptosis. J Neuropathol Exp Neurol. 1999;15:1001-1011.
63. Wada S., Yone K., Ishidou Y., et al. Apoptosis following spinal cord injury in rats and preventative effect of N-methyl-d-aspartate receptor antagonist. J Neurosurg. 1999;91:98-104.
64. Emery E., Aldana P., Bunge M.B., et al. Apoptosis after traumatic human spinal cord injury. J Neurosurg. 1998;89:911-920.
65. Bunge R.P., Puckett W.R., Becerra J.L., et al. Observations on the pathology of human spinal cord injury. Adv Neurol. 1993;59:75-89.
66. Kroemer G., Petit P., Zamzami N., et al. The biochemistry of programmed cell death. FASEB J. 1995;9:1277-1287.
67. Tymianski M., Tator C.H. Normal and abnormal calcium homeostasis in neurons: a basis for the pathophysiology of traumatic and ischemic central nervous system injury. Neurosurgery. 1996;38:1176-1195.
68. Banasiak K.J., Haddad G.G. Hypoxia-induced apoptosis: effect of hypoxic severity and role of p53 in neuronal cell death. Brain Res. 1998;797:295-304.
69. Griffiths I.R. Spinal cord blood flow after acute experimental cord injury in dogs. J Neurol Sci. 1976;27:247-259.
70. Gwag B.J., Lobner D., Koh J.Y., et al. Blockade of glutamate receptors unmasks neuronal apoptosis after oxygen-glucose deprivation in vitro. Neuroscience. 1995;68:615-619.
71. Lee Y.B., Yune T.Y., Baik S.Y., et al. Role of tumor necrosis factor-alpha in neuronal and glial apoptosis after spinal cord injury. Exp Neurol. 2000;166:190-195.
72. Genovese T., Melani A., Esposito E., et al. The selective adenosine A2A receptor agonist CGS2168 reduces JNK MAPK activation in oligodendrocytes in injured spinal cord. Shock. 2009;32:578-585.
73. Genovese T., Esposito E., Mazzon E., et al. Beneficial effects of ethyl pyruvate in a mouse model of spinal cord injury. Shock. 2009;32:217-227.
74. Raff M.C., Barres B.A., Burne J.F., et al. Programmed cell death and the control of cell survival: lessons from the nervous system. Science. 1993;262:695-700.
75. Barres B.A., Jacobsen M.D., Schmid R. Does oligodendrocyte survival depend on axons? Curr Biol. 1993;3:489-497.
76. Warden P., Bamber N.I., Li H., et al. Delayed glial cell death following wallerian degeneration in white matter tracts after spinal cord dorsal column cordotomy in adult rats. Exp Neurol. 2001;168:213-224.
77. Vartanian T., Goodearl A., Viehover A., et al. Axonal neuregulin signals cells of the oligodendrocyte lineage through activation of HER4 and Schwann cells through HER2 and HER3. J Cell Biol. 1997;137:211-220.
78. Gehrmann J., Banati R.B. Microglial turnover in the injured CNS: activated microglia undergo delayed DNA fragmentation following peripheral nerve injury. J Neuropathol Exp Neurol. 1995;54:680-688.
79. Shuman S.L., Bresnahan J.C., Beattie M.S. Apoptosis of microglia and oligodendrocytes after spinal cord contusion in rats. J Neurosci Res. 1997;50:798-808.
80. Beattie M.S., Bresnahan J.C., Masters J.N., et al. Incidence of apoptotic nuclear profiles in Xenopus laevis central nervous system is increased by exogenous thyroid hormone exposure. Soc Neurosci Abstr. 1995;21:1305.
81. Chuaqui R., Tapia J. Histologic assessment of the age of recent brain infarcts in man. J Neuropathol Exp Neurol. 1993;52:481-489.
82. Baba H., Maezawa Y., Imura S., et al. Quantitative analysis of the spinal cord motoneuron under chronic compression: an experimental observation. J Neurol. 1996;243:109-116.
83. Yamazaki M., Moriya H., Goto S., et al. Increased type XI collagen expression in the spinal hyperostotic mouse (twy/twy). Calcif Tissue Int. 1991;48:182-189.
84. Yamaura I., Yone K., Nakahara S., et al. Mechanism of destructive pathologic changes in the spinal cord under chronic mechanical compression. Spine (Phila Pa 1976). 2002;27:21-26.
85. Inukai T., Uchida K., Nakajima H., et al. Tumor necrosis factor-alpha and its receptors contribute to apoptosis of oligodendrocytes in the spinal cord of spinal hyperostotic mouse (twyy/twy) sustaining chronic mechanical compression. Spine (Phila Pa 1976). 2009;34:2848-2857.
86. Bresnahan J.C. An electron-microscopic analysis of axonal alteration following blunt contusion of the spinal cord of the rhesus monkey. J Neurol Sci. 1978;37:59-82.
87. Blight A.R. Delayed demyelination and macrophage invasion: a candidate for secondary cell damage in spinal cord injury. CNS Trauma. 1985;2:299-314.
88. Brand A., Yavin E. Early ethanolamine phospholipid translocation marks stress-induced apoptotic cell death in oligodendroglial cells. J Neurochem. 2001;78:1208-1218.
89. Emoto K., Toyama-Sorimachi N., Karasuyama H., et al. Exposure of phosphatidylethanolamine on the surface of apoptotic cells. Exp Cell Res. 1997;232:430-434.
90. Alexander-North L.S., North J.A., Kiminyo K.P., et al. Polyunsaturated fatty acids increase lipid radical formation induced by oxidant stress in endothelial cells. J Lipid Res. 1994;35:1773-1785.
91. Zurita M., Vaquero J., Oya S., et al. Effects of dexamethasone on apoptosis-related cell death after spinal cord injury. J Neurosurg. 2002;96(Suppl 1):83-89.
92. Xu F., Fan G., Chen S., et al. Methylprednisolone inhibition of TNF-α expression and NF-κB activation after spinal cord injury in rats. Mol Brain Res. 1998;59:135-142.
93. Ha K., Carragee E., Cheng I., et al. Pregabalin as a neuroprotector after spinal cord injury in rats: biochemical analysis and effect on glial cells. J Korean Med Sci. 2011;26:404-411.
94. Rowland J.W., Hawryluk G.W., Kwon B., et al. Current status of acute spinal cord injury pathophysiology and emerging therapies: promise on the horizon. Neurosurg Focus. 2008;25:E2.
95. Keane R.W., Kraydieh S., Lotocki G., et al. Apoptotic and anti-apoptotic mechanisms following spinal cord injury. J Neuropathol Exp Neurol. 2001;60:422-429.
96. Citron B.A., Arnold P.M., Haynes N.G., et al. Neuroprotective effects of caspase-3 inhibition on functional recovery and tissue sparing after acute spinal cord injury. Spine (Phila Pa 1976). 2008;33:2269-2277.
97. Austin J.W., Fehlings M.G. Molecular mechanisms of Fas-mediated cell death in oligodendrocytes. J Neurotrauma. 2008;25:411-426.
98. Louis J.-C., Magal E., Takayama S., Varon S. CNTF protection of oligodendrocytes against natural and tumor necrosis factor-induced death. Science. 1993;259:689-692.
99. Mayer M., Noble M. N-acetyl-l-cysteine is a pluripotent protector against cell death and enhancer of trophic factor-mediated cell survival in vitro. Proc Natl Acad Sci U S A. 1994;91:7496-7500.
100. Smith C.A., Farrah T., Goodwin R.G. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell. 1994;76:959-962.
101. Glazner G.W., Mattson M.P. Differential effects of BDNF, ADNF9, and TNF-α on levels of NMDA receptor subunits, calcium homeostasis, and neuronal vulnerability to excitotoxicity. Exp Neurol. 2000;161:442-452.
102. Bruce A.J., Bolong W., Kindy M.S., et al. Altered neuronal and microglial responses to excitotoxic and ischemic brain injury in mice lacking TNF receptors. Nat Med. 1996;2:788-794.
103. Scherbel U., Raghupathi R., Nakamura M., et al. Differential acute and chronic responses of tumor necrosis factor-deficient mice to experimental brain injury. Proc Natl Acad Sci U S A. 1999;96:8721-8726.
104. Lenardo M.J., Baltimore D. NF-κB, a pleiotropic mediator of inducible and tissue-specific gene control. Cell. 1989;58:227-229.
105. Wang C.X., Nuttin B., Heremans H., et al. Production of tumor necrosis factor in spinal cord following traumatic injury in rats. J Neuroimmunol. 1996;69:151-156.
106. Tamatani M., Che Y.H., Matsuzaki H., et al. Tumor necrosis factor induces Bcl-2 and Bcl-x expression through NF-κB activation in primary hippocampal neurons. J Biol Chem. 1999;274:8531-8538.
107. Chen C., Edelstein L.C., Gelinas C. The Rel/NF-κB family directly activates expression of the apoptosis inhibitor Bcl-xL. Mol Cell Biol. 2000;20:2687-2695.
108. Chu Z.L., McKinsey T.A., Liu L., et al. Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-κB control. Proc Natl Acad Sci U S A. 1997;94:10057-10062.
109. Rothe M., Pan M.G., Henzel W.J., et al. The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. Cell. 1995;83:1243-1252.
110. Xue D., Horvitz H.R. Inhibition of the Caenorhabditis elegans cell-death protease CED-3 by a CED-3 cleavage site in baculovirus p35 protein. Nature. 1995;377:248-251.
111. Uren A.G., Pakusch M., Hawkins C.J., et al. Cloning and expression of apoptosis inhibitory protein homologs that function to inhibit apoptosis and/or bind tumor necrosis factor receptor-associated factors. Proc Natl Acad Sci U S A. 1996;93:4974-4978.
112. Roy N., Devereaux Q.L., Takahashi R., et al. The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO J. 1997;16:6914-6925.
113. Wang C.Y., Mayo M.W., Korneluk R.G., et al. NF-κB anti-apoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science. 1998;281:1680-1683.
114. Kim G.-M., Xu J., Song S.-K., et al. Tumor necrosis factor receptor deletion reduces nuclear factor-kappa B activation, cellular inhibitor of apoptosis protein 2 expression, and functional recovery after traumatic spinal cord injury. J Neurosci. 2001;21:6617-6625.
115. Bethea J.R., Nagashima H., Acosta M.C., et al. Systemically administered interleukin-10 reduces tumor necrosis factor-alpha production and significantly improves functional recovery following spinal cord injury in rats. J Neurotrauma. 1999;16:851-863.
116. Ruddle N.H., Bergman C.M., McGrath K.M., et al. An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis. J Exp Med. 1990;172:1193-1200.
117. Selmaj K., Raine C.S., Cannella B., Brosnan C.F. Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J Clin Invest. 1991;87:949-954.
118. Seto K., Abe M., Ohya O., et al. A rat model of HTLV-1 infection: development of chronic progressive myeloneuropathy in seropositive WKAH rats and related apoptosis. Acta Neuropathol. 1995;89:483-490.
119. Jiang X., Ikeda H., Tomaru U., et al. A rat model for human T lymphocyte virus type I-associated myeloneuropathy: down-regulation of bcl-2 expression and increase in sensitivity to TNF-alpha of the spinal oligodendrocytes. J Neuroimmunol. 2000;106:105-113.
120. Lou J., Lenke L.G., Ludwig F.J., et al. Apoptosis as a mechanism of neuronal cell death following acute experimental spinal cord injury. Spinal Cord. 1998;36:683-690.
121. Yong C., Arnold P.M., Zoubine M.N., et al. Apoptosis in cellular compartment of rat spinal cord after severe contusion injury. J Neurotrauma. 1998;15:459-472.
122. Abe Y., Yamamoto T., Sugiyama Y., et al. Apoptotic cells associated with wallerian degeneration after experimental spinal cord injury: a possible mechanism of oligodendroglial death. J Neurotrauma. 1999;16:946-952.
123. Li G.L., Farooque M., Holtz A., et al. Apoptosis of oligodendrocytes occurs for long distances away from the primary injury after compression trauma to rat spinal cord. Acta Neuropathol. 1999;98:473-480.
124. Trapp B.D., Nishiyama A., Cheng D., et al. Differentiation and death of premyelinating oligodendrocytes in developing rodent brain. J Cell Biol. 1997;137:459.
125. Tang D.G., Tokumoto Y.M., Apperly J.A., et al. Lack of replicating senescence in cultured rat oligodendrocyte precursor cells. Science. 2001;291:868.
126. Barres B.A., Raff M.C. Proliferation of oligodendrocyte precursor cells depends on electrical activity in axons. Nature. 1993;361:258.
127. Mason J.L., Ye P., Suzuki K., et al. Insulin-like growth factor-1 inhibits mature oligodendrocyte apoptosis during primary demyelination. J Neurosci. 2000;20:5703-5708.
128. Grinspan J.B., Stern J.L., Franceshini B., et al. Trophic effects of basic fibroblast growth factor (bFGF) on differentiated oligodendroglia: a mechanism for regeneration of the oligodendroglial lineage. J Neurosci Res. 1993;36:672-680.
129. Yasuda T., Grinspan J.B., Stern J.L., et al. Apoptosis occurs in the oligodendroglial lineage and is prevented by basic fibroblast growth factor. J Neurosci Res. 1995;40:306-317.
130. Bansal E., Pfeiffer S.E. FGF-2 converts mature oligodendrocytes to a novel phenotype. J Neurosci Res. 1997;50:215-228.
131. Rus H.G., Niculescu F., Shin M.L. Sublytic complement attack induces cell cycle in oligodendrocytes. J Immunol. 1996;156:4892-4900.
132. Halperin J.A., Taratusca A., Nicholson-Weller A. Terminal complement complex C5b-9 stimulates mitogenesis in 3T3 cells. J Clin Invest. 1993;91:1974-1978.
133. Rus H.G., Niculescu F.I., Shin M.L. Role of the C5b-9 complement complex in cell cycle and apoptosis. Immunol Rev. 2001;180:49-55.
134. Hengartner M.O. The biochemistry of apoptosis. Nature. 2000;407:770-776.
135. Ellis R.E., Yuan J., Horvitz H.R. Mechanisms and functions of cell death. Annu Rev Cell Biol. 1991;7:663-698.
136. McDonald J.W., Althomsons S.P., Hyrc K.L., et al. Oligodendrocytes from forebrain are highly vulnerable to AMPA/kainate receptor-mediated excitotoxicity. Nat Med. 1998;4:291-297.
137. Rosenberg L.J., Teng Y.D., Wrathall J.R. 2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline reduces glial loss and acute white matter pathology after experimental spinal cord contusion. J Neurosci. 1999;19:464-475.
138. Povlishock J.T., Jenkins L.W. Are the pathobiological changes evoked by traumatic brain injury immediate and irreversible? Brain Pathol. 1995;5:415-426.
139. Jafari S.S., Maxwell W.L., Neilson M., et al. Axonal cytoskeletal changes after non-disruptive axonal injury. J Neurocytol. 1997;26:207-221.
140. Jafari S.S., Nielson M., Graham D.I., et al. Axonal cytoskeletal changes after nondisruptive axonal injury. 2. Intermediate sized axons. J Neurotrauma. 1998;15:955-966.
141. Geddes J.F., Vowles G.H., Hackshaw A.K., et al. Neuropathology of inflicted head injury in children: 2. Microscopic brain injury in infants. Brain. 2001;124:1299-1306.
142. Ichihara K., Taguchi T., Sakuramoto I., et al. Mechanism of the spinal cord injury and the cervical spondylotic myelopathy: new approach based on the mechanical features of the spinal cord white and gray matter. J Neurosurg. 2003;99:278-285.
143. Galbraith J.A., Thibault L.E., Matteson D.R. Mechanical and electrical responses of the squid giant axon to simple elongation. J Biomech Eng. 1993;115:13-17.
144. Henderson F.C., Geddes J.F., Crockard H.A. Neuropathology of the brainstem and spinal cord in end stage rheumatoid arthritis: implications for treatment. Ann Rheum Dis. 1993;52:629-637.
145. Henderson F.C., Geddes J.F., Vaccaro A.R., et al. Stretch-associated injury in cervical spondylotic myelopathy: new concept and review. Neurosurgery. 2005;56:1101-1113.
146. Henderson F.C., Wilson W.A., Mott S., et al. Deformative stress associated with an abnormal clivo-axial angle: a finite element analysis. Surg Neurol Int. 2010;1:30.
147. Eleraky M.A., Llanos C., Sonntag V.K. Cervical corpectomy: report of 185 cases and review of the literature. J Neurosurg. 1999;90(Suppl 1):35-41.
148 Wolf J.A., Stys P.K., Lusardi T., et al. Traumatic axonal injury induces calcium influx modulated by tetrodotoxin-sensitive sodium channels. J Neurosci. 2001;21:1923-1930.
149. Arundine M., Aarts M., Lau A., et al. Vulnerability of central neurons to secondary insults after in vitro mechanical stretch. J Neurosci. 2004;24:8106-8123.
150. Saatman K.E., Abai B., Grosvenor A., et al. Traumatic axonal injury results in biphasic calpain activation and retrograde transport impairment in mice. J Cereb Blood Flow Metab. 2003;23:34-42.
151. Cornelissen J., Armstrong J., Holt C.M. Mechanical stretch induces phosphorylation of p38-MAPK and apoptosis in human saphenous vein. Arterioscler Thromb Vasc Biol. 2004;24:451-456.
152. Beilharz E.J., Williams C.E., Dragunow M., et al. Mechanisms of delayed cell death following hypoxic-ischemic injury in the immature rat: evidence for apoptosis during selective neuronal loss. Mol Brain Res. 1995;29:1-14.
153. Hill I.E., McManus J.P., Rasquinha I., et al. DNA fragmentation indicative of apoptosis following unilateral cerebral hypoxia-ischemia in the neonatal rat. Brain Res. 1995;676:398-403.
154. Vela J.M., Dalmau I., Gonzalez B., et al. The microglial reaction in spinal cords of jimpy mice is related to apoptotic oligodendrocytes. Brain Res. 1996;712:134-142.
155. Kruman I., Bruce-Kellar A.J., Bredsen D., et al. Evidence that 4-hydroxynonenal mediates oxidative stress-induced neuronal apoptosis. J Neurosci. 1997;17:5089-5100.
156. Gary D.S., Bruce-Kellar A.J., Kindy M.S., et al. Ischemic and excitotoxic brain injury is enhanced in mice lacking the p55 tumor necrosis factor receptor. J Cereb Blood Flow Metab. 1998;18:1283-1287.
157. Sullivan P.G., Bruce-Kellar A.J., Rabchevsky A.G., et al. Exacerbation of damage and altered NF-κB activation in mice lacking tumor necrosis factor receptors after traumatic brain injury. J Neurosci. 1999;19:6248-6256.
158. Boje K.M., Arora P.K. Microglial-produced nitric oxide and reactive nitrogen oxides mediate neuronal cell death. Brain Res. 1992;587:250.
159. Chao C.C., Hu S., Molitor T.W., et al. Activated microglia mediate neuronal cell injury via a nitric oxide mechanism. J Immunol. 1992;149:2736.
160. Arnett H.A., Hellendall R.P., Matsushima G.K., et al. The protective role of nitric oxide in a neurotoxicant induced demyelinating model. J Immunol. 2002;168:427-433.
